Graminex® Rye Pollen Achieves Novel Food Registration in China and Appoints Guangzhou Narnia Biotechnology as Their Authorized Distribution Partner
8.8.2023 03:00:00 EEST | Business Wire | Press release
Graminex® announced today that it has achieved novel food registration in China for Rye Pollen and appointed Guangzhou Narnia Biotechnology as its distribution partner in China.
Graminex®, based in the United States, is the exclusive grower and manufacturer of rye pollen and a leader in the international dietary supplement industry, with products sold in more than 47 countries. Graminex’s vertically integrated manufacturing ensures quality, consistency, and efficacy of their products. Guangzhou Narnia Biotech will represent Graminex® Rye Pollen active ingredients, as well as the dietary supplements, primarily focusing on the areas of prostate health, women’s health, and liver support.
“We are very excited about the opportunity to market high quality dietary ingredients that have been recently registered in China,” said Daniel Guo, General Manager, Narnia Biotech. “Our market is increasingly looking for high-quality dietary products. Our cooperation with Graminex® will strengthen Narnia’s offering to our customers and is in line with Narnia’s strategy of partnering with innovative producers of unique ingredients.”
Heather J. May, CEO of Graminex® said, “Narnia Biotech has a reputation of unmatched customer service and technical capabilities, including lab testing and product formulation. I am confident that through their expertise and attention to product safety and quality assurance, they are the right distribution partner for Graminex in China.”
About Guangzhou Narnia Biotechnology Co., Ltd
Narina is headquartered in TIMES E-PARK, Tianhe District, Guangzhou, with an R&D Center in Guangzhou. Its branch in Beijing extends their network throughout China. Narnia’s mission to create a safe, natural, and nutritious life is based on commitments to integration and promotion of functional food ingredients. With current market trends and continuously developing formulation technology, Narnia provides customers one-stop procurement solutions, as well as value-added services such as market analysis, project launching, formula design, and production guidance. Visit www.narniabiotech.com.
About Graminex ® L.L.C.
Graminex® is the leading producer of solvent-free Graminex® Rye Pollen. Graminex® owns and manages over 6,500 farm acres in Ohio to meet customer’s needs. Graminex’s active ingredients are grown and processed for the dietary supplement, nutraceutical, pharmaceutical, food and skincare industries, focusing on prostate health, urinary care, menopausal support. Visit www.graminex.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230807107912/en/
Contact information
Colleen E. May
CBO
+1 (419) 278-1023
graminex@graminex.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SERI Lugano Launches International Scientific Outreach Initiative on Light-Based Neuroscience and Pineal Gland Research18.5.2026 16:38:00 EEST | Press release
As scientific interest in light-based stimulation, neuroendocrine regulation, and integrative medicine continues to grow internationally, the Switzerland Eye Research Institute (SERI Lugano) has launched a new international scientific outreach initiative focused on public engagement and interdisciplinary research communication in neuroscience and cellular modulation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515840289/en/ Ophthalmologist Roberto Pinelli explains, in an engaging personal narrative style, his unique methods for using a combination of light, sound, and nutraceuticals to non-invasively activate the pineal gland to promote cellular rejuvenation, decrease aging, and improve overall well-being. Supported by case studies and peer-reviewed research, Pinelli’s method centers on using photons to convey vibrational energy through the eyes to target areas of the body with the sinergic use of sound vibrations and
TwentyTwo Real Estate to Acquire Terhills Resort in Belgium from LRM18.5.2026 16:00:00 EEST | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces it has agreed to acquire Terhills Resort in Belgium from LRM. The transaction is expected to close on 29 May 2026. Operated by Center Parcs, the premium holiday park spans 63 hectares and comprises 250 waterfront cottages alongside central leisure facilities, set within a unique natural environment at the gateway to Hoge Kempen National Park. Center Parcs will remain the operator of the resort for at least the next 10 years, ensuring continuity for guests and supporting the long-term positioning of the resort as a leading leisure destination in Limburg, one of Flanders’ most distinctive tourism regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513424487/en/ Opened in 2021, Terhills Resort forms part of the broader long-term transformation of the surrounding area into a leading nature, tourism and leisure destination.
Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden18.5.2026 15:30:00 EEST | Press release
Thermo Fisher Scientific, the world leader in serving science, today announced the opening of a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, located within GoCo Health Innovation City. This new facility expands the company’s global bioanalytical capabilities to support pharmaceutical and biotechnology customers across all phases of drug development. With state-of-the-art instrumentation and Good Laboratory Practice (GLP) capabilities, the laboratory provides rapid, reliable bioanalytical and biomarker services across the full drug development lifecycle, from preclinical studies through post-approval. Its advanced technology suite includes cell-based assays, immunochemistry, liquid chromatography-mass spectrometry, molecular genomics, flow cytometry and proteomics, supporting both small molecules and complex therapeutic modalities such as peptides, antibodies, oligonucleotides, and cell and gene therapies. “Our new Gothenburg laboratory is purpose-built to address t
HistoSonics Receives Landmark TFDA Approval in Taiwan, Accelerating Global Expansion18.5.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has received approval from the Taiwan Food and Drug Administration (TFDA) for the Edison® System, representing a significant milestone in the company’s global expansion efforts and continued growth across Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518694013/en/ HistoSonics Edison® Histotripsy System Taiwan is widely recognized as one of the most advanced and strategically important medical device markets in the region, known for its rigorous regulatory standards and highly innovative physician community. The TFDA approval process included a detailed review of the company’s clinical and regulatory submission package and concluded with unanimous agreement from committee members. The approval further reinforces the growing clinical and regulatory momentum behind histotripsy, a non-invasive, non-th
FurtherAI Appoints Tom Bradley to Lead UK and EU Expansion18.5.2026 15:00:00 EEST | Press release
FurtherAI, the AI platform purpose-built for insurance, today announced the appointment of Tom Bradley to lead its UK and EU operations. This marks a significant step in FurtherAI's international expansion, as the company moves to establish a local presence in one of the world's most important insurance markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518611218/en/ FurtherAI Appoints Tom Bradley to lead UK & EU expansion FurtherAI is already working with leading partners in the UK, and Tom's appointment will allow the company to deepen those relationships, build a local team, and serve the rapidly growing demand from carriers, MGAs, and brokers across the Lloyd's market and the wider region. A market moving fast on AI The Lloyd's market and the broader UK and European insurance ecosystem are adopting AI at a pace few would have predicted even twelve months ago. From submission gateways to policy audits to claims, o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom